Wave Life Sciences, Inc. (WVE)
WVE moved a median of -0.14% 30 minutes after news, and +0.51% by the close. How WVE actually reacts to news — the realized, point-in-time move the market made, measured across 323 labeled events over the last three years with zero look-ahead.
WVE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 304 |
| 30-min | -0.14% | 45% | 304 |
| 60-min | +0.14% | 52% | 304 |
| to close | +0.51% | 53% | 299 |
| Middle 50% of WVE reactions | -2.22% to +1.49% |
|---|---|
| Median reaction (30-min) | -0.14% |
| Measured reactions | 323 |
Half of all Wave Life Sciences, Inc. news events land between -2.22% and +1.49% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How WVE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 19 | +0.04% | 53% | +2.66% |
| Analyst downgrades | 12 | +0.36% | 50% | -0.36% |
| Coverage initiations | 39 | -1.22% | 28% | -2.78% |
| Rating reiterations | 87 | -0.13% | 45% | -0.32% |
| Price-target raises | 17 | -0.07% | 41% | +0.75% |
| Price-target cuts | 10 | +0.22% | 60% | +0.62% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how WVE ranks against every other measured name →
That’s how WVE usually reacts — get an email when it moves on news →Email me when WVE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to WVE's baseline. Nothing else.
Recent WVE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Wave Life Sciences, Inc. | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form POS AM Wave Life Sciences, Inc. | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form POSASR Wave Life Sciences, Inc. | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS Wave Life Sciences, Inc. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Wave Life Sciences Announces Completion of Redomiciliation to Delaware | Press release | GlobeNewswire | -3.90% | — | |
| Form 8-K12B Wave Life Sciences, Inc. For: Aug 07 | SEC filing · Form 8-K12B | SEC EDGAR | -3.90% | — | |
| Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware | Press release | GlobeNewswire | +1.01% | +1.52% | |
| Wave Life Sciences to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.70% | +4.35% | |
| Form 10-Q Wave Life Sciences Ltd. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.07% | +2.49% | |
| Form 8-K Wave Life Sciences Ltd. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +1.07% | +2.49% | |
| Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.07% | +2.49% | |
| Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026 | Press release | GlobeNewswire | +1.69% | +2.66% | |
| Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation | Press release | GlobeNewswire | +1.11% | -0.95% | |
| Form 8-K Wave Life Sciences Ltd. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +1.66% | +1.92% | |
| Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases | Press release | GlobeNewswire | +1.32% | -1.81% | |
| Wave Life Sciences to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -2.92% | -3.69% | |
| Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 | Press release | PR Newswire | +0.31% | -5.54% | |
| Form 8-K Wave Life Sciences Ltd. For: May 18 | SEC filing · Form 8-K | SEC EDGAR | +0.48% | -1.29% | |
| Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing | Press release | GlobeNewswire | +0.48% | -1.29% | |
| Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference | Press release | GlobeNewswire | -1.00% | -1.71% | |
| Form DEF 14A Wave Life Sciences Ltd. For: Jun 22 | SEC filing · Form DEF | SEC EDGAR | +0.28% | -0.14% | |
| Form PRER14A Wave Life Sciences Ltd. | SEC filing · Form PRER14A | SEC EDGAR | +1.38% | +2.75% | |
| Form 10-K/A Wave Life Sciences Ltd. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.99% | +3.39% | |
| Form 10-Q Wave Life Sciences Ltd. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.25% | +4.16% | |
| Form 8-K Wave Life Sciences Ltd. For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | -1.25% | +4.16% | |
| Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.25% | +4.16% | |
| Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026 | Press release | GlobeNewswire | -0.40% | -0.94% | |
| Form 8-K Wave Life Sciences Ltd. For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | -0.40% | -0.94% | |
| Form DEFA14A Wave Life Sciences Ltd. | SEC filing · Form DEFA14A | SEC EDGAR | -0.40% | -0.94% | |
| Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States | Press release | GlobeNewswire | -0.40% | -0.94% | |
| Form 8-K Wave Life Sciences Ltd. For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -3.81% | |
| Form DEFA14A Wave Life Sciences Ltd. | SEC filing · Form DEFA14A | SEC EDGAR | -0.46% | -3.81% | |
| Form PRE 14A Wave Life Sciences Ltd. For: Apr 15 | SEC filing · Form PRE | SEC EDGAR | -0.46% | -3.81% | |
| Wave Life Sciences Announces Proposed Redomiciliation to the United States | Press release | GlobeNewswire | -0.46% | -3.81% | |
| Form 8-K Wave Life Sciences Ltd. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -1.49% | +15.67% | |
| Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007 | Press release | GlobeNewswire | -1.49% | +15.67% | |
| Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference | Press release | GlobeNewswire | +1.33% | -2.15% | |
| Form 10-K Wave Life Sciences Ltd. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.28% | +5.71% | |
| Form 8-K Wave Life Sciences Ltd. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -0.28% | +5.71% | |
| Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.28% | +5.71% | |
| Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +3.52% | +0.07% | |
| Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026 | Press release | GlobeNewswire | -1.14% | +0.38% | |
| Form 8-K Wave Life Sciences Ltd. For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | +2.68% | +5.83% | |
| Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency | Press release | GlobeNewswire | +2.68% | +5.83% | |
| Form 8-K Wave Life Sciences Ltd. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.69% | +0.51% | |
| Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio | Press release | GlobeNewswire | +0.69% | +0.51% | |
| Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -1.21% | -4.70% | |
| Form 8-K Wave Life Sciences Ltd. For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | +0.15% | -15.49% | |
| Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants | Press release | GlobeNewswire | -6.81% | -0.93% | |
| Form 8-K Wave Life Sciences Ltd. For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | +6.51% | +45.26% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the WVE section they belong to.
Where else WVE is measured.
WVE earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Bionano Genomics, Inc. (BNGO) | 324 | -0.95% | 31% |
| Senseonics Holdings, Inc. (SENS) | 323 | -0.54% | 41% |
| Voyager Therapeutics, Inc. (VYGR) | 322 | -0.12% | 41% |
| Viking Therapeutics, Inc. (VKTX) | 320 | -0.62% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Wave Life Sciences, Inc.'s median reaction calculated?
Every labeled WVE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 323 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of WVE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does WVE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.